Speciality Medicines IPO

The company plans to establish an R&D centre to overcome limitations of third-party manufacturing including slower product development cycles, higher outsourcing costs, and delays in regulatory approvals. The facility will enable pre-formulation studies, formulation development, analytical method validation, stability testing and scale-up processes in compliance with Good Laboratory Practices.

The company intends to register products across multiple international markets including Jordan, Ethiopia, Namibia, Uganda, and Peru to expand global footprint and meet country-specific regulatory requirements. Additionally, funds will be utilized for product development activities through third-party service providers to strengthen presence in international markets.

The company aims to enhance visibility, strengthen brand equity, and support sales growth across existing and emerging markets through strategic marketing initiatives. Funds will be utilized for participation in global exhibitions including CPHI Worldwide events and Arab Health to showcase product portfolio and engage with stakeholders.

The company intends to utilize funds to finance day-to-day operations, fund product registrations in new geographies, and strengthen supply chain relationships. This investment will provide necessary liquidity to manage operations, ensure timely fulfillment of domestic and export orders, and support the strategic goal of becoming a research-driven specialty pharmaceutical company.

The amount utilized for general corporate purposes shall not exceed percent of the Gross Proceeds or specified amount, whichever is lower, in accordance with applicable regulations.